TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03127267: Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Sponsor: AB Science · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 495 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,631,010

Rescue Site Savings

+$3,729,630

Unlock Full NCT03127267 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03127267 Rescue Dossier →